Sagimet advances AURORA Phase 3 acne trial of denifanstat, targets Q4 2026 enrollment

• Sagimet advanced its AURORA U.S. Phase 3 trial of oral acne drug denifanstat toward first patient enrollment in Q4 2026.
• No new trial results were presented; patient screening is expected to start in October 2026, with enrollment shortly thereafter.
• The study is designed to test whether denifanstat can improve moderate to severe acne versus placebo, with a long-term safety follow-up.
• Sagimet expects to submit an NDA once the initial 12-week blinded portion is completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250700PRIMZONEFULLFEED9815366) on August 25, 2026, and is solely responsible for the information contained therein.